dotMD.com
Bacterial, Viral & Fungal Infections • ICD-10-CM A03.9

Shigella infection

Audited by the DotMD AI Specialist Council • FDA DailyMed SPL: 2026-11-02 • ICD-10-CM A03.9 • 4 Linked .gov / PubMed Citations • Governance: Dr. Priya Nair, MD, FAAD (NPI #1295730425)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary

Shigella infection Key Takeaways

Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about Shigella infection

3 of 3 Free Questions Remaining

What Is Shigella infection?

Recognized across U.S. clinical coding as A03.9 (Infections & Antivirals), Shigella infection is evaluated via sepsis/severity red-flag triage [Shigella infection A03.9] to align day-to-day symptom relief with long-term physiological stability.

Pathophysiology, Underlying Causes & Clinical Presentation

At the cellular and tissue level in infections & antivirals, Shigella infection (A03.9) involves or latent viral in Shigella infection (A03.9: reactivation within sensory). progression correlates with shifts in C-Reactive Protein / in Shigella infection (A03.9: Procalcitonin) (Resolution to baseline (A03.9)).

Common Symptoms & Clinical Signs

  • • Presentation of Shigella infection (A03.9): regional lymph node in Shigella infection (A03.9: tenderness or acute)
  • • Secondary Shigella infection clinical sign: acute fever, chills, in Shigella infection (A03.9: malaise, and myalgias)
  • • Symptom flares in Shigella infection correlating with C-Reactive Protein / in Shigella infection (A03.9: Procalcitonin) deviation outside Resolution to baseline (A03.9)
  • • Functional infections & antivirals impact requiring sepsis/severity red-flag triage [Shigella infection A03.9] evaluation (A03.9)

Shigella infection Diagnostic Classification & Lab Markers

Metric Verified Benchmark Source
ICD-10-CM Diagnostic Code A03.9 WHO / CMS ICD-10-CM Clinical Classification
Clinical Specialty Hub Bacterial, Viral & Fungal Infections NLM Clinical Tables
Diagnostic / Lab Marker: C-Reactive Protein / in Shigella infection (A03.9: Procalcitonin) Resolution to baseline (A03.9) Clinical Reference Target Range
Diagnostic / Lab Marker: Targeted PCR / in Shigella infection (A03.9: Culture & Sensitivity) Pathogen clearance / negative test (A03.9) Clinical Reference Target Range
Diagnostic / Lab Marker: Complete Blood Count in Shigella infection (A03.9: (WBC & Differential)) WBC 4.0 – 10.0 x10^3/uL (A03.9) Clinical Reference Target Range
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance

FDA-Monographed Medications & Public Cash Price Reference for Shigella infection

Check Drug Interactions →

Treatment selection for Shigella infection depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.

Dr. Lin (AI PubMed Clinical Trial Lead)

Peer-Reviewed Human Clinical Trials & Meta-Analyses (Shigella infection)

Browse All PubMed Translations →
Study & Plain-English Finding Sample (N) Rigor Primary Source
New Insights on Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster: What a 1,426-Participant Study Found

In participants ≥50 years with prior HZ, RZV does not increase HZ recurrence risk.

The Journal of infection • 2025-09-15 • Phase III Randomized Trial
N = 1,426 96/100 PMID 40780591 ↗
Can This Approach Help? Inside the Latest Research on Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in

MenACYW-TT booster induced robust immunogenicity against all serogroups, regardless of the primary vaccine received, and had an acceptable safety profile.

Pediatric research • 2023-09-15 • Phase III Randomized Trial
Multi-cohort 82/100 PMID 36899125 ↗
Zero-PHI Patient Support & Cohort Discussions

Shigella infection Patient Community & “People Like Me” Threads

“People Like Me” Cohort Filter (Zero-PHI)

Filter Shigella infection community threads and patient logs by age, biological sex, dosage, and treatment duration.

No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Shigella infection.

Related Conditions in Bacterial, Viral & Fungal Infections